<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01989585</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-02103</org_study_id>
    <secondary_id>NCI-2013-02103</secondary_id>
    <secondary_id>13-424</secondary_id>
    <secondary_id>18-716</secondary_id>
    <secondary_id>9466</secondary_id>
    <secondary_id>9466</secondary_id>
    <secondary_id>U01CA132194</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <secondary_id>UM1CA186688</secondary_id>
    <secondary_id>UM1CA186709</secondary_id>
    <secondary_id>UM1CA186716</secondary_id>
    <nct_id>NCT01989585</nct_id>
    <nct_alias>NCT01970956</nct_alias>
  </id_info>
  <brief_title>Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma</brief_title>
  <official_title>Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and&#xD;
      navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or&#xD;
      solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by&#xD;
      surgery (unresectable). Dabrafenib, trametinib, and navitoclax may stop the growth of tumor&#xD;
      cells by blocking some of the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD), toxicity, and safety profile of navitoclax&#xD;
      when given in combination with dabrafenib and trametinib in patients with BRAF-mutant solid&#xD;
      tumors. (Phase I) II. To estimate the complete response (CR) rate in patients with&#xD;
      BRAF-mutant melanoma treated with dabrafenib, trametinib, and navitoclax as compared to the&#xD;
      historical control dabrafenib and trametinib combination (DT). (Phase II) III. To compare the&#xD;
      maximal tumor regression in patients with BRAF-mutant melanoma treated with dabrafenib,&#xD;
      trametinib versus dabrafenib, trametinib, and navitoclax. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To describe pharmacodynamics effects of treatment with dabrafenib, trametinib, and&#xD;
      navitoclax on both serial tumor biopsies and serial blood draws in a small subset of patients&#xD;
      treated with BRAF-mutant melanoma. (Phase I) II. To describe the pharmacokinetics of&#xD;
      treatment with dabrafenib, trametinib, and navitoclax. (Phase I) III. To compare the&#xD;
      progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in&#xD;
      patients with BRAF-mutant melanoma treated with dabrafenib, trametinib, versus dabrafenib,&#xD;
      trametinib, and navitoclax. (Phase II) IV. To compare the degree of apoptosis induced in&#xD;
      on-treatment biopsies of patients with BRAF-mutant melanoma treated with dabrafenib,&#xD;
      trametinib versus dabrafenib, trametinib, and navitoclax. (Phase II) V. To explore other&#xD;
      pharmacodynamic effects in on-treatment biopsies of patients with BRAF-mutant melanoma&#xD;
      treated with either dabrafenib, trametinib versus dabrafenib, trametinib, and navitoclax&#xD;
      including cell proliferation (Ki-67), proteomics (reverse-phase protein microarrays [RPPA]),&#xD;
      and B-cell chronic lymphocytic leukemia (CLL)/lymphoma 2 (BCL-2) family gene expression&#xD;
      analysis. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of dabrafenib, trametinib, and navitoclax&#xD;
      followed by a randomized phase II study.&#xD;
&#xD;
      PHASE I: Patients receive navitoclax orally (PO) once daily (QD) on days -7 to -1 of cycle 1&#xD;
      only. Patients also receive dabrafenib PO twice daily (BID), trametinib PO QD, and navitoclax&#xD;
      PO QD days 1-28. Cycles repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also&#xD;
      receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After the completion of study treatment, patients are followed up for clinical evaluation at&#xD;
      28 days and every 3 months thereafter until disease progression or death, whichever comes&#xD;
      first. For survival follow up, patients are followed every 12 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose of the combination of dabrafenib, trametinib, and navitoclax (Phase I)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Determined by dose-limiting toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with a complete response (CR) (Phase II)</measure>
    <time_frame>Up to 4 weeks after last study treatment</time_frame>
    <description>Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, in the cohort of patients treated with dabrafenib, trametinib, and navitoclax (DTN). The proportion of patients with a best response of CR will be presented with a 95% confidence interval calculated using the method of Atkinson and Brown.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal degree of tumor regression (Phase II)</measure>
    <time_frame>Up to 4 weeks after last study treatment</time_frame>
    <description>A comparison between the maximal tumor regression for patients treated with DTN and dabrafenib and trametinib (DT) will be conducted using a Wilcoxon rank-sum test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) (Phase II)</measure>
    <time_frame>Time from start of treatment to time of progression or death, whichever occurs first, assessed for up to 4 years</time_frame>
    <description>PFS will be summarized using the Kaplan-Meier. Log-rank tests will be used to assess for indications of differences between the two treatment modalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>OS will be summarized using the Kaplan-Meier. Log-rank tests will be used to assess for indications of differences between the two treatment modalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) (Phase II)</measure>
    <time_frame>Up to 4 weeks after last study treatment</time_frame>
    <description>ORRs will be presented with 95% exact, binomial confidence intervals.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in terminal deoxynucleotidyl transferase 2´-deoxyuridine, 5´-triphosphate (dUTP) nick end labeling assay (TUNEL) staining</measure>
    <time_frame>Baseline to up to 1 week</time_frame>
    <description>Fold changes of TUNEL will be calculated (post/pre). A Wilcoxon rank-sum test will be used to compare the ratios (or equivalently, the difference in the natural logs) of baseline and follow-up levels of TUNEL between DTN and DT treatment arms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in B-cell chronic lymphocytic leukemia/lymphoma 2 (BCL-2)</measure>
    <time_frame>Baseline to up to 1 week</time_frame>
    <description>Will be primarily descriptive.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Ki67</measure>
    <time_frame>Baseline to up to 1 week</time_frame>
    <description>Will be primarily descriptive.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in phosphatase and tensin homolog (PTEN) status</measure>
    <time_frame>Baseline to up to 1 week</time_frame>
    <description>Will be primarily descriptive.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fold changes in BRAF-mutation assay</measure>
    <time_frame>Baseline to up to 4 weeks after last study treatment</time_frame>
    <description>Fold-changes in assay response will be calculated (post/pre). Fold changes in the assay will be compared across RECIST responses using the Kruskal-Wallis test. In addition, for assay-based response or progression, the proportions of patients with CR/partial response (PR), stable disease (SD), or progressive disease (PD) will be presented with exact 90% confidence intervals. Assay performance data will be compared with response. The proportions will be summarized and compared using exact confidence intervals. Behavior of the blood assay will be summarized graphically.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fold changes in tumor burden</measure>
    <time_frame>Baseline to up to 4 weeks after last study treatment</time_frame>
    <description>Assay fold changes will be compared with fold changes in tumor burden (post/pre). The relationship will be summarized graphically and using the Spearman rank correlation. Differences in the behavior of the assay will be explored using a general linear model of log (fold-change) with study, baseline tumor burden, and log (fold-change tumor burden) as predictors.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters, including maximal plasma or serum concentration (Cmax), area under the curve to the last collection point (AUClast), area under the curve for dose interval (AUC0-t), and time of maximal concentration (Tmax)</measure>
    <time_frame>Pre-treatment, 1, 2, 4, 6, 8, and 24 hours post-treatment on days 1 and 15 of cycle 1, and day 1 of cycles 2, 4, 8, and 12 (each cycle = 28 days)</time_frame>
    <description>Descriptive statistics including mean, standard deviation, coefficient of variation, geometric mean, median, minimum and maximum will be computed for each pharmacokinetic variable; descriptive statistics for natural-log transformed pharmacokinetic variables will also be provided.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Stage III Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <condition>Unresectable Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm I (dabrafenib, trametinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (dabrafenib, trametinib)</arm_group_label>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
    <other_name>BRAF Inhibitor GSK2118436</other_name>
    <other_name>GSK-2118436</other_name>
    <other_name>GSK-2118436A</other_name>
    <other_name>GSK2118436</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (dabrafenib, trametinib)</arm_group_label>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Navitoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
    <other_name>A-855071.0</other_name>
    <other_name>ABT-263</other_name>
    <other_name>BcI-2 Family Protein Inhibitor ABT-263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (dabrafenib, trametinib)</arm_group_label>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (dabrafenib, trametinib)</arm_group_label>
    <arm_group_label>Arm II (dabrafenib, trametinib, and navitoclax)</arm_group_label>
    <other_name>GSK1120212</other_name>
    <other_name>JTP-74057</other_name>
    <other_name>MEK Inhibitor GSK1120212</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PHASE I SUBJECTS ONLY: Prior therapy is allowed; for patients enrolled in the Phase I&#xD;
             portion of the study, patients may have received any number of prior lines of therapy&#xD;
             including treatment with a BRAF and/or MEK inhibitor; prior navitoclax use will not be&#xD;
             allowed, unless the patient received &lt; 7 days of navitoclax lead-in on this or another&#xD;
             study and had to stop for reasons other than toxicity or disease progression&#xD;
&#xD;
          -  Patients must have histologically confirmed, BRAF-mutant (V600E/K) melanoma&#xD;
             (molecularly confirmed using validated, commercially available assay performed in a&#xD;
             Clinical Laboratory Improvement Act [CLIA]-approved laboratory) that is metastatic or&#xD;
             unresectable and for which standard curative measures do not exist or are no longer&#xD;
             effective&#xD;
&#xD;
               -  If test at CLIA-certified lab used a non-Food and Drug Administration (FDA)&#xD;
                  approved method, information about the assay must be provided; (FDA approved&#xD;
                  tests for BRAF V600 mutations in melanoma include: THxID BRAF Detection Kit and&#xD;
                  Cobas 4800 BRAF V600 Mutation Test)&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm with conventional&#xD;
             techniques or as &gt;= 10 mm with spiral computed tomography (CT) scan, magnetic&#xD;
             resonance imaging (MRI), or calipers by clinical exam&#xD;
&#xD;
          -  Prior therapy is allowed; for patients enrolled in the Phase II portion of the study,&#xD;
             patients may have received prior immunotherapy (including high-dose IL-2, ipilimumab,&#xD;
             nivolumab, and other anti-PD1/PDL1 antibodies) or chemotherapy; however prior&#xD;
             navitoclax, BRAF inhibitor and/or MEK inhibitor therapy will not be allowed&#xD;
&#xD;
          -  Age &gt;= 18 years. Because no dosing or adverse event data are currently available on&#xD;
             the use of navitoclax in combination with dabrafenib and trametinib in patients &lt; 18&#xD;
             years of age, children are excluded from this study, but will be eligible for future&#xD;
             pediatric trials&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1 (Karnofsky &gt;= 70%)&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dl (patients may be transfused to this level)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal OR &gt; 1.5 x institutional&#xD;
             upper limit of normal allowed if direct bilirubin is within normal range&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x institutional upper limit of normal&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin&#xD;
             time (PTT) &lt; 1.3 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL OR creatinine clearance &gt;= 50 mL/min/1.73 m^2&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= institutional lower limit of normal (LLN) by&#xD;
             echocardiogram (ECHO)&#xD;
&#xD;
          -  Patients must have a corrected QT (QTc) interval of less than 480 msec&#xD;
&#xD;
          -  The effects of navitoclax, dabrafenib, and trametinib on the developing human fetus&#xD;
             are unknown; for this reason, women of child-bearing potential and men with partners&#xD;
             of childbearing potential must agree to use adequate contraception (barrier method of&#xD;
             birth control, or abstinence; hormonal contraception is not allowed due to drug-drug&#xD;
             interactions which can render hormonal contraceptives ineffective) prior to study&#xD;
             entry, for the duration of study participation, and for 4 months after completion of&#xD;
             study drug administration; should a woman become pregnant or suspect she is pregnant&#xD;
             while she is participating in this study, she should inform her treating physician&#xD;
             immediately; based on studies in animals, it is also known that dabrafenib may cause&#xD;
             damage to the tissue that makes sperm; this may cause sperm to be abnormal in shape&#xD;
             and size and could lead to infertility, which may be irreversible; safety and efficacy&#xD;
             of the combination of dabrafenib and trametinib in pediatric populations have not been&#xD;
             investigated; dabrafenib or trametinib-dabrafenib combination should not be&#xD;
             administered to pediatric populations outside clinical trials&#xD;
&#xD;
          -  Able to swallow and retain oral medication and must not have any clinically&#xD;
             significant gastrointestinal abnormalities that may alter absorption such as&#xD;
             malabsorption syndrome or major resection of the stomach or bowels&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document;&#xD;
             if a patient has impaired decision-making capacity, a legally authorized&#xD;
             representative, patients will be allowed to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PHASE I SUBJECTS ONLY: Patients must not have received prior navitoclax, unless the&#xD;
             patient received &lt; 7 days of navitoclax lead-in on this or another study and had to&#xD;
             stop for reasons other than toxicity or disease progression&#xD;
&#xD;
          -  Patients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior&#xD;
             to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy&#xD;
             with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy,&#xD;
             or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or&#xD;
             trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks&#xD;
             preceding the first dose of study treatment; biologics will not be allowed within 30&#xD;
             days prior to, or during, navitoclax administration&#xD;
&#xD;
          -  Prior navitoclax, BRAF inhibitor, and MEK inhibitor is prohibited; (exceptions for&#xD;
             Phase I are described above)&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents have received any other&#xD;
             investigational drugs within 28 days (or five half-lives, whichever is shorter; with a&#xD;
             minimum of 14 days from the last dose) preceding the first dose of study treatment and&#xD;
             during the study&#xD;
&#xD;
          -  Patients with treated leptomeningeal or brain metastasis are not eligible unless there&#xD;
             is demonstrated stability (documented by imaging) for &gt;= 3 months from any prior&#xD;
             treatment of leptomeningeal or brain metastasis. Treatment may include surgery,&#xD;
             radiation or systemic therapy. Patients with untreated leptomeningeal or brain&#xD;
             metastasis or requiring corticosteroids are not eligible. Subjects on a stable dose of&#xD;
             corticosteroids &gt; 1 month or who have been off of corticosteroids for at least 2 weeks&#xD;
             can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical&#xD;
             monitor. Subjects must also be off of enzyme-inducing anticonvulsants for &gt; 4 weeks&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to navitoclax, dabrafenib, or trametinib, or excipients or to dimethyl&#xD;
             sulfoxide (DMSO)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             serious infection, symptomatic congestive heart failure, unstable angina pectoris,&#xD;
             cardiac arrhythmia, uncontrolled diabetes, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because navitoclax, dabrafenib, and&#xD;
             trametinib may have teratogenic or abortifacient effects; because there is an unknown&#xD;
             but potential risk for adverse events in nursing infants secondary to treatment of the&#xD;
             mother with the study drugs, breastfeeding should be discontinued if the mother is&#xD;
             treated with the study drugs&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy that predict to interact with any of the study drugs are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with the study drugs; appropriate&#xD;
             studies will be undertaken in patients receiving combination antiretroviral therapy&#xD;
             when indicated; it is not necessary to conduct HIV testing at screening; patients who&#xD;
             are HIV-positive with undetectable viral loads, not on interacting antiretroviral&#xD;
             therapy, and have CD4 counts above 300/mm^3 may be eligible after discussion with the&#xD;
             principal investigator&#xD;
&#xD;
          -  History of another malignancy; exception: patients who have been disease-free for 3&#xD;
             years (depending upon tumor type studied or clinical setting, 3 or 5 years can be&#xD;
             used; e.g., for advanced melanoma and pancreatic studies 3 years is more appropriate&#xD;
             due to aggressiveness of the disease, while 5 years can be more appropriate for&#xD;
             prostate or ovarian cancer or adjuvant setting when life expectancy is longer), or&#xD;
             patients with a history of completely resected non-melanoma skin cancer and/or&#xD;
             patients with indolent secondary malignancies, are eligible; consult the CTEP medical&#xD;
             monitor if unsure whether second malignancies meet the requirements specified above;&#xD;
             exception: patients with history of RAS mutation-positive tumors are not eligible&#xD;
             regardless of interval from the current study; prospective RAS testing is not&#xD;
             required; however, if the results of previous RAS testing are known, they must be used&#xD;
             in assessing eligibility&#xD;
&#xD;
          -  History of interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  History or current evidence/risk of retinal vein occlusion (RVO) or central serous&#xD;
             retinopathy (CSR):&#xD;
&#xD;
               -  History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled&#xD;
                  glaucoma or ocular hypertension, uncontrolled systemic disease such as&#xD;
                  hypertension, diabetes mellitus, or history of hyperviscosity or&#xD;
                  hypercoagulability syndromes)&#xD;
&#xD;
               -  Visible retinal pathology as assessed by ophthalmic exam that is considered a&#xD;
                  risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence&#xD;
                  of new visual field defects, and intraocular pressure &gt; 21 mmHg&#xD;
&#xD;
          -  History or evidence of cardiovascular risk including any of the following:&#xD;
&#xD;
               -  A QT interval corrected for heart rate using the Bazett's formula QTcB &gt;= 480&#xD;
                  msec on screening electrocardiography (ECG)&#xD;
&#xD;
               -  History or evidence of current clinically significant uncontrolled arrhythmias&#xD;
                  (exception: patients with controlled atrial fibrillation for &gt; 30 days prior to&#xD;
                  randomization are eligible)&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction and unstable&#xD;
                  angina), coronary angioplasty, or stenting within 6 months prior to randomization&#xD;
&#xD;
               -  History or evidence of current &gt;= class II congestive heart failure as defined by&#xD;
                  the New York Heart Association (NYHA) functional classification system&#xD;
&#xD;
               -  Treatment-refractory hypertension defined as a blood pressure of systolic &gt; 140&#xD;
                  mmHg and/or diastolic &gt; 90 mmHg which cannot be controlled by anti-hypertensive&#xD;
                  therapy&#xD;
&#xD;
               -  Abnormal cardiac valve morphology (&gt;= grade 2) documented by echocardiogram&#xD;
                  (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be&#xD;
                  entered on study); subjects with moderate valvular thickening should not be&#xD;
                  entered on study&#xD;
&#xD;
          -  Known history of hepatitis B virus (HBV), or hepatitis C virus (HCV) infection&#xD;
             (patients with chronic or cleared HBV and HCV infection are eligible); it is not&#xD;
             necessary to conduct HBV and HCV testing at screening&#xD;
&#xD;
          -  Subject has an underlying condition predisposing them to bleeding or currently&#xD;
             exhibits signs of clinically significant bleeding&#xD;
&#xD;
          -  Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated&#xD;
             bleeding within 1 year prior to the first dose of study drug&#xD;
&#xD;
          -  A history of glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Unresolved toxicity of National Cancer Institute Common Terminology Criteria for&#xD;
             Adverse Events, version 5.0 (NCI CTCAE v. 5.0) grade 2 or higher from previous&#xD;
             anti-cancer therapy, except alopecia or an endocrine toxicity related to immunotherapy&#xD;
             (e.g. thyroiditis/hypothyroidism, adrenal insufficiency, hypophysitis) requiring&#xD;
             replacement therapy, at the time of randomization&#xD;
&#xD;
          -  Due to the expected dose-limiting toxicity of thrombocytopenia, the following&#xD;
             concomitant medications are not allowed during navitoclax administration: clopidogrel,&#xD;
             ibuprofen, tirofiban, warfarin, and other anticoagulants, drugs, or herbal supplements&#xD;
             that affect platelet function are excluded, with the exception of low-dose&#xD;
             anticoagulation medications (such as heparin) that are used to maintain the patency of&#xD;
             a central intravenous catheter; aspirin will not be allowed within 7 days prior to the&#xD;
             first dose of navitoclax or during navitoclax administration; however, subjects who&#xD;
             have previously received aspirin therapy for thrombosis prevention may resume a low&#xD;
             dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (&gt;=&#xD;
             50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding&#xD;
             treatment with aspirin therapy will be determined by the investigator in conjunction&#xD;
             with the medical monitor&#xD;
&#xD;
          -  Current use of a prohibited medication; the following medications or non-drug&#xD;
             therapies are prohibited:&#xD;
&#xD;
               -  Other anti-cancer therapy while on study treatment; (note: megestrol [Megace] if&#xD;
                  used as an appetite stimulant is allowed)&#xD;
&#xD;
               -  Concurrent treatment with bisphosphonates is permitted; however, treatment must&#xD;
                  be initiated prior to the first dose of study therapy; prophylactic use of&#xD;
                  bisphosphonates in patients without bone disease is not permitted, except for the&#xD;
                  treatment of osteoporosis&#xD;
&#xD;
               -  Because the composition, pharmacokinetics (PK), and metabolism of many herbal&#xD;
                  supplements are unknown, the concurrent use of all herbal supplements is&#xD;
                  prohibited during the study (including, but not limited to, St. John's wort,&#xD;
                  kava, ephedra [ma huang], ginkgo biloba, dehydroepiandrosterone [DHEA], yohimbe,&#xD;
                  saw palmetto, or ginseng)&#xD;
&#xD;
               -  Anticoagulants or antiplatelet agents except for low-dose, aspirin&#xD;
&#xD;
          -  Preclinical studies indicate that navitoclax is metabolized by CYP3A4, is a moderate&#xD;
             inhibitor of CYP2C8, and is a strong inhibitor of CYP2C9; there is also evidence of&#xD;
             interactions with dabrafenib; therefore, caution should be exercised when dosing&#xD;
             navitoclax concurrently with CYP2C8 and CYP2C9 substrates; common CYP2C8 substrates&#xD;
             include paclitaxel, statins, and glitazones, whereas CYP2C9 substrates include&#xD;
             phenytoin; when possible, investigators should switch to alternative medications or&#xD;
             monitor the patients closely; CYP3A inhibitors such as ketoconazole and clarithromycin&#xD;
             are not allowed 7 days prior to the first dose of navitoclax or during navitoclax&#xD;
             administration&#xD;
&#xD;
          -  Patients receiving any medications or substances that are strong inhibitors or&#xD;
             inducers of CYP3A or CYP2C8 are ineligible; current use of, or intended ongoing&#xD;
             treatment with: herbal remedies (e.g., St. John's wort), or strong inhibitors or&#xD;
             inducers of permeability-glycoprotein (Pgp) or breast cancer resistance protein 1&#xD;
             (Bcrp1) should also be excluded; below are a few examples of the agents:&#xD;
&#xD;
               -  Strong inducers of CYP3A or CYP2C8, since concentrations of dabrafenib may be&#xD;
                  decreased:&#xD;
&#xD;
                    -  Antibiotics: rifamycin class agents (e.g., rifampin, rifabutin, rifapentine)&#xD;
&#xD;
                    -  Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin,&#xD;
                       s-mephenyto&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan J Sullivan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber - Harvard Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital in Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Oncology/Hematology-Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine Health/Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Justin T. Moyers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>720-848-0650</phone>
    </contact>
    <investigator>
      <last_name>Theresa M. Medina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>954-461-2180</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Coral Gables</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Kendall</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center - McKinley Campus</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Zeynep Eroglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Zeynep Eroglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HaysMed University of Kansas Health System</name>
      <address>
        <city>Hays</city>
        <state>Kansas</state>
        <zip>67601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-623-5774</phone>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Lawrence Memorial Hospital</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-505-2800</phone>
      <email>Stephanie.Norris@LMH.ORG</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olathe Health Cancer Center</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-355-8000</phone>
      <email>Jeni.wakefield@olathehealth.org</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center-Overland Park</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Indian Creek Campus</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Via Christi - Pittsburg</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>620-235-7900</phone>
      <email>jennifer.jameson@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salina Regional Health Center</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-452-7038</phone>
      <email>mleepers@srhc.com</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Health System Saint Francis Campus</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-295-8000</phone>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan J. Sullivan</last_name>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Ryan J. Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Truman Medical Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>816-404-4375</phone>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - North</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center at North Kansas City Hospital</name>
      <address>
        <city>North Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Gary C. Doolittle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Christian Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2013</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

